ERK and JNK activation is essential for oncogenic transformation by v-Rel

Oncogene

Volumn 29, Issue 47, 2010, Pages 6267-6279

  Kralova, J ^a,b   Sheely, J I ^a   Liss, A S ^a,c   Bose, H R ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

MAPK; NF B; oncogenesis; transformation; v Rel

Indexed keywords

I KAPPA B; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CARCINOGENICITY; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST; INTRACELLULAR SIGNALING; LYMPHOCYTE; LYMPHOID CELL LINE; LYMPHOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETROVIRUS INFECTION; SPLEEN CELL;

ANIMALS; CELL LINE; CELL TRANSFORMATION, VIRAL; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE KNOCKDOWN TECHNIQUES; GENES, REL; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; PHENOTYPE; RNA, SMALL INTERFERING;

AVES;

EID: 78649508571     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.359     Document Type: Article

References (50)

1. Basseres DS, Baldwin AS. (2006). Nuclear factor-kB and inhibitor of kB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817-6830.
2. Blume-Jensen P, Hunter T. (2001). Oncogenic kinase signalling. Nature 411: 355-365.
3. Bode AM, Dong Z. (2007). The functional contrariety of JNK. Mol Carcinog 46: 591-598.
4. Bonizzi G, Karin M. (2004). The two NF-kB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280-288.
5. Bost F, McKay R, Bost M, Potapova O, Dean NM, Mercola D. (1999). The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol Cell Biol 19: 1938-1949.
6. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC et al. (1999). Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59: 803-806.
7. Bunting K, Rao S, Hardy K, Woltring D, Denyer GS, Wang J et al. (2007). Genome-wide analysis of gene expression in T cells to identify targets of the NF-kB transcription factor c-Rel. J Immunol 178: 7097-7109.
8. 2-terminal kinase-2-deficient mice. Cancer Res 61: 3908-3912.
9. Corzo C, Corominas JM, Tusquets I, Salido M, Bellet M, Fabregat X et al. (2006). The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genet Cytogenet 165: 151-156.
10. Courtois-Cox S, Jones SL, Cichowski K. (2008). Many roads lead to oncogene-induced senescence. Oncogene 27: 2801-2809.
11. Dhillon AS, Hagan S, Rath O, Kolch W. (2007). MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290.
12. Dutta J, Fan Y, Gupta N, Fan G, Gelinas C. (2006). Current insights into the regulation of programmed cell death by NF-kB. Oncogene 25: 6800-6816.
13. Fujii M, Minamino T, Nomura M, Miyamoto KI, Tanaka J, Seiki M. (1996). Selective activation of the proto-oncogene c-jun promoter by the transforming protein v-Rel. Oncogene 12: 2193-2202.
14. Gilmore TD. (1999). Multiple mutations contribute to the oncogeni-city of the retroviral oncoprotein v-Rel. Oncogene 18: 6925-6937.
15. Gilmore TD, Kalaitzidis D, Liang MC, Starczynowski DT. (2004). The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene 23: 2275-2286.
16. Gupta N, Delrow J, Drawid A, Sengupta AM, Fan G, Gelinas C. (2008). Repression of B-cell linker (BLNK) and B-cell adaptor for phosphoinositide 3-kinase (BCAP) is important for lymphocyte transformation by rel proteins. Cancer Res 68: 808-814.
17. Hayden MS, Ghosh S. (2004). Signaling to NF-kB. Genes Dev 18: 2195-2224.
18. Holtmann H, Winzen R, Holland P, Eickemeier S, Hoffmann E, Wallach D et al. (1999). Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduc-tion pathways. Mol Cell Biol 19: 6742-6753.
19. Houben R, Vetter-Kauczok CS, Ortmann S, Rapp UR, Broecker EB, Becker JC. (2008). Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol 128: 2003-2012.
20. Karakosta A, Golias C, Charalabopoulos A, Peschos D, Batistatou A, Charalabopoulos K. (2005). Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia. J Exp Clin Cancer Res 24: 505-514.
21. Karin M. (2006). Nuclear factor-kB in cancer development and progression. Nature 441: 431-436.
22. Kennedy NJ, Sluss HK, Jones SN, Bar-Sagi D, Flavell RA, Davis RJ. (2003). Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev 17: 629-637.
23. Kralova J, Liss AS, Bargmann W, Bose Jr HR. (1998). AP-1 factors play an important role in transformation induced by the v-rel oncogene. Mol Cell Biol 18: 2997-3009.
24. Kralova J, Schatzle JD, Liss AS, Bargmann W, Bose Jr HR. (1996). Synergistic stimulation of avian IkBa transcription by rel and fos/ jun factors. Oncogene 12: 2595-2604.
25. Lin A. (2003). Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays 25: 17-24.
26. Liss AS, Tiwari R, Kralova J, Bose Jr HR. (2010). Cell transformation by v-Rel reveals distinct roles of AP-1 family members in Rel/NF-kB oncogenesis. Oncogene 29: 4925-4937.
27. Majid SM, Liss AS, You M, Bose Jr HR. (2006). The suppression of SH3BGRL is important for v-Rel-mediated transformation. Oncogene 25: 756-768.
28. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K et al. (1994). Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970.
29. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F et al. (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284.
30. Murphy LO, Blenis J. (2006). MAPK signal specificity: the right place at the right time. Trends Biochem Sci 31: 268-275.
31. Nehyba J, Hrdlickova R, Bose Jr HR. (1997). Differences in kB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein. Oncogene 14: 2881-2897.
32. Nelson DM, Wahlfors JJ, Chen L, Onodera M, Morgan RA. (1998). Characterization of diverse viral vector preparations, using a simple and rapid whole-virion dot-blot method. Hum Gene Ther 9: 2401-2405.
33. 2-terminal kinase 2 is required for Ras transformation independently of activator protein 1. Cancer Res 67: 178-185.
34. Okuno H, Suzuki T, Yoshida T, Hashimoto Y, Curran T, Iba H. (1991). Inhibition of jun transformation by a mutated fos gene: design of an anti-oncogene. Oncogene 6: 1491-1497.
35. Oleinik NV, Krupenko NI, Krupenko SA. (2007). Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway. Oncogene 26: 7222-7230.
36. 2-terminal kinase 2-mediated tumor growth regulation revealed by serial analysis of gene expression. Cancer Res 62: 3257-3263.
37. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB et al. (2009). (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 106: 4519-4524.
38. Raman M, Chen W, Cobb MH. (2007). Differential regulation and properties of MAPKs. Oncogene 26: 3100-3112.
39. Robinson MJ, Stippec SA, Goldsmith E, White MA, Cobb MH. (1998). A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr Biol 8: 1141-1150.
40. Cip1. Mol Cell Biol 17:5588-5597
41. Shaulian E, Karin M. (2002). AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131-E136.
42. Skarpen E, Flinder LI, Rosseland CM, Orstavik S, Wier0d L, Oksvold MP et al. (2008). MEK1 and MEK2 regulate distinct functions by sorting ERK2 to different intracellular compartments. FASEB J 22: 466-476.
43. Suzukawa K, Weber TJ, Colburn NH. (2002). AP-1, NF-kB, and ERK activation thresholds for promotion of neoplastic transformation in the mouse epidermal JB6 model. Environ Health Perspect 110: 865-870.
44. Tsavachidou D, Coleman ML, Athanasiadis G, Li S, Licht JD, Olson MF et al. (2004). SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Res 64: 5556-5559.
45. 1/S transition. J Biol Chem 279: 43861-43869.
46. Whitmarsh AJ, Davis RJ. (2007). Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene 26: 3172-3184.
47. Cip1. Mol Cell Biol 17: 5598-5611.
48. 2-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 9: 391-401.
49. Yoon S, Seger R. (2006). The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24: 21-44.
50. Zheng C, Xiang J, Hunter T, Lin A. (1999). The JNKK2-JNK1 fusion protein acts as a constitutively active c-Jun kinase that stimulates c-Jun transcription activity. J Biol Chem 274: 28966-28971.